Every letter we have printed

The population most at risk on this endpoint is the one least represented in the trials, which is a general feature of trial recruitment and a specific problem here. Extrapolating a bone result across age bands is not supportable.

Density and quality are different properties and only the first is measured. A change in density with unchanged architecture and a change in both have very different implications, and the common instrument cannot distinguish them.

The figures that circulate are cumulative incidence over a whole trial, and they are read as though they described how somebody feels in a given week. Those are very different quantities, and the second is much smaller than the first. Your table separating them is the most useful thing published on this in a while.

The first-dose period accounts for a disproportionate share of reported events, and reporting a single study-wide incidence hides that structure entirely. A rate by week would be far more informative than a rate by trial.

The mechanistic account in your piece moves from receptor distribution to symptom rather quickly. The intermediate steps — motility, accommodation, secretion — are each measurable and each studied separately, and collapsing them makes the story tidier than the evidence.

The literature on this class and the general gastroenterological literature barely reference each other, which is odd given how much of the second is directly relevant. Cross-citation would be the cheapest improvement available.

An effect is dose-limiting when it stops the escalation, and that is a decision rather than a symptom threshold. Your framing makes that visible, which matters because the same symptom is tolerable in one person’s circumstances and not in another’s.

In this market the dose is a calculation performed by the buyer from a concentration they inferred, which introduces a source of variation absent from any trial. Anything read across from the trial literature carries that additional uncertainty.

Anything described as a management strategy in this context is an intervention on top of an intervention, and the interaction is unstudied in every case I have looked at. That is worth stating whenever one is mentioned.

Anything in this area is squarely a matter for the clinician conducting the procedure, and a publication’s job is to describe what the professional guidance says and where it differs. Yours does that and stops, which is right.

Attrition within a substudy is usually higher than in the parent trial because it asks more of the participant. The analysed population at the final scan can be a small fraction of those enrolled, and that number is often only in the supplement.

The body-composition substudies were substudies, and the number of participants scanned is a small fraction of the trial. That does not invalidate them and it does mean the confidence intervals are wide, which is worth printing beside the point estimates that circulate.

The activity component in these protocols is described in a sentence and would take a page to reproduce. Without the page, no reader can tell whether their own practice resembles what was studied.

The word conforms is doing exactly the work you describe. A result of 97.8 against a specification of not less than 95 conforms; so does 99.6. The certificate that prints only the verdict has told me the material passed a test whose difficulty I am not allowed to know.

On the difference between a release specification and a shelf-life specification: outside a regulated setting almost nobody distinguishes them, and it matters. A limit that a lot met on the day it was made is not a promise about the lot in the drawer eighteen months later, and the certificate is a photograph rather than a warranty.

You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.

The instrument-class section is the most useful thing you have printed on this subject. A unit-resolution quadrupole cannot distinguish a deamidation from the parent, and a great many identity confirmations in this trade are performed on exactly that class of instrument. The report says the mass matched, and it did, at the resolution available.

Isotope envelopes are where resolution becomes visible to a non-specialist. At low resolving power a peptide is a hump; at high resolving power it is a comb whose spacing tells you the charge state directly. If the report shows a hump, the instrument has not answered the question you paid it to answer.

On your point about D-amino acids: chiral amino-acid analysis after hydrolysis is not exotic and several contract laboratories offer it. The obstacle is that hydrolysis itself racemises a few per cent of most residues, so the method has a blank problem, and interpreting a low-level D content is genuinely difficult rather than merely expensive.

Your charge-state arithmetic is correct and I would set it out for readers as a rule they can apply. Take the observed mass-to-charge value, multiply by the charge, then subtract the charge multiplied by the mass of a proton. Two adjacent peaks in an envelope give you the charge and therefore the mass without any assumption at all.

A note from a reader in a laboratory rather than a clinic. The technical material is accurate often enough that I now check my assumptions against it rather than the other way round.

Percentage of loss and absolute loss give different impressions of the same result, and writers choose between them according to the argument. Printing both is trivial and would end most of the disagreement I read.

The units confusion is worth naming. Lean mass, fat-free mass and muscle mass are three different quantities measured by three different methods, and they are used interchangeably in almost every account I read.

Site restriction is rarely mentioned. Substudies requiring a scanner run only at centres with one, and those centres differ systematically from the rest of the trial network in population and practice.

A caution on the word high-resolution as it appears in marketing. It is not a threshold; it is a continuum, and instruments separated by a factor of twenty in resolving power are sold under the same adjective. Ask for the figure and the mass at which it was obtained, and the adjective becomes unnecessary.

Your worked example separates two species one dalton apart and treats that as the hard case. The hard case in practice is fourteen milli-daltons, which is what distinguishes a genuine methyl group from a substitution nobody wanted. That gap needs an order of magnitude more resolving power than most service instruments deliver.

Receptor occupancy arguments are used loosely in this discussion. Occupancy and effect are related by a function that is rarely linear, and quoting a saturation figure as though it settled the question is not supported by the pharmacology.

Dose-ranging studies are the most informative and least cited part of this literature. They were run before the approved schedules were settled and they contain the evidence everybody is now arguing about without reading.

Splitting an interval changes the peak-to-trough ratio and not the average exposure, which is a distinction with real consequences and no supporting outcome data in this class.

A mass spectrum reproduced at postage-stamp size in the corner of a certificate is decoration rather than evidence. If the document is going to carry the spectrum, it should carry it at a size where the isotope pattern is readable, or it should carry the data file reference instead.

Ask for the acquisition method file, not the report. The report is a rendering of a decision; the method file is the decision. Two laboratories will send you the same one-page summary from acquisitions that have almost nothing in common.

Sample transport time affects analytes that continue to be metabolised in the tube. A postal sample and a sample analysed on site are not equivalent, and postal collection is increasingly common.

Recent strenuous activity moves several markers into ranges that look alarming and resolve in days. Anybody arranging their own testing should record what they did the day before, and almost nobody does.

The reference population for most intervals is a convenience sample of donors or staff, and its age and sex composition is rarely printed with the interval. Where it is, it is often not the population reading the result.

Administrative burden is a reason with no name. Reordering, storing, reconstituting, timing — a small load that accumulates, and people stop because it became tiresome rather than because anything went wrong. It is invisible in every dataset because no question asks about it.

Reading across your coverage, the thing that most changes reported reasons is who is asking. That should be a headline finding rather than a methodological footnote, because it undermines comparison between every study in the field.

The regain trajectory is presented as a mean curve and the variation around it is very wide. Some participants hold most of the change and some return close to baseline, and the average describes neither of them well.

Intermittent schedules are being used and are essentially unstudied, and the pharmacokinetics make the reasoning awkward: with a long half-life the concentration does not fall to nothing between doses, so an interrupted schedule is not the same as stopping and restarting.

A note on language from a reader who works in health communication. Maintenance implies a plateau, sustained implies effort, continued implies a decision. Three words for the same phase, each carrying a different picture of who is responsible for the outcome.

The most useful figure in your maintenance coverage was the proportion who had discontinued by a stated month, printed with the trial and the year. It is a dull number and it puts every other claim in proportion.